In conclusion, this study identified for the first time three germline variants in the OPN and CD44 genes that individually or jointly influenced clinical outcome and prognosis in inoperable NSCLC patients treated with curative RT doses and in patients with SCC. This evidence concerns the gene CD44 and non-small cell lung carcinoma.